title: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
abstract: OBJECTIVE
  MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed.
  
  
  METHODS
  In the phase I portion, MDX-060 was administered intravenously at doses of 0.1, 1, 5, or 10 mg/kg weekly for 4 weeks to cohorts of three to six patients. Twenty-one patients--16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell lymphoma--were enrolled. Because of the lack of a defined MTD or dose-response correlation, the phase II portion was amended to include several dose levels. In the phase II portion, an additional 51 patients, 47 with HL and four with ALCL, were treated at doses of 1, 5, 10, and 15 mg/kg.
  
  
  RESULTS
  MDX-060 was well tolerated, and an MTD has not been identified. Only 7% of patients experienced grade 3 or 4 treatment-related adverse events. Among the 72 patients treated, clinical responses were observed in six. Twenty-five patients had stable disease, including five who remained free from progression 1 year after treatment.
  
  
  CONCLUSIONS
  MDX-060 was well tolerated at doses up to 15 mg/kg. MDX-060 has limited activity as a single agent, but the minimal toxicity observed and the significant proportion of patients with stable disease suggests that further study of MDX-060 in combination with other therapies is warranted.
authors.affiliation: Division of Hematology, Mayo Clinic School of Medicine, Rochester, MN 55905, USA. ansell.stephen@mayo.edu
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Ansell
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Khuda Dad
authors.initials: KD
authors.lastname: Khan
authors.forename: Thomas
authors.initials: T
authors.lastname: Lin
authors.forename: Roger
authors.initials: R
authors.lastname: Strair
authors.forename: Tibor
authors.initials: T
authors.lastname: Keler
authors.forename: Robert
authors.initials: R
authors.lastname: Graziano
authors.forename: Diann
authors.initials: D
authors.lastname: Blanset
authors.forename: Michael
authors.initials: M
authors.lastname: Yellin
authors.forename: Steven
authors.initials: S
authors.lastname: Fischkoff
authors.forename: Albert
authors.initials: A
authors.lastname: Assad
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D017730:Ki-1 Antigen / Q000276:immunology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D017730:Ki-1 Antigen; C510955:iratumumab